Skip to content
Subscriber Only

AstraZeneca Approaches Gilead About Potential Merger

  • U.K. drugmaker contacted Gilead last month; no formal talks
  • Deal with $96 billion U.S. firm would be record in health care
Video player cover image
AstraZeneca Is Said to Approach Gilead About Potential Merger
Updated on

AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.

The U.K.-based firm informally contacted Gilead last month to gauge its interest in a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren’t in formal talks, the people added.